# To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

> **NCT05212701** · PHASE2 · WITHDRAWN · sponsor: **Dompé Farmaceutici S.p.A**

## Conditions studied

- Fatigue
- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Reparixin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05212701
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04-19
- **Primary completion:** 2023-06
- **Final completion:** 2024-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Dompé decided to withdraw the study due to the numerous difficulties encountered in enrollment, mainly due to the rapidly and continuously changing oncology drug scenario . No patients were enrolled.
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212701, "To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05212701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*